Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 5/20 | 0.61 |
| ▸ | NOS2 | P35228 | 5/20 | 0.61 |
| ▸ | NOS1 | P29475 | 4/20 | 0.61 |
| ▸ | GABRP | O00591 | 2/20 | 0.53 |
| ▸ | GABRD | O14764 | 2/20 | 0.53 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.53 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.53 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.53 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.53 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.53 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.53 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.53 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.53 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.53 |
| ▸ | GABRE | P78334 | 2/20 | 0.53 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.53 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.53 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.53 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL31330594 | 1.00 | NOS3 (0.61) | NOS3NOS2NOS1GABRPGABRD | |
| SCHEMBL3333363 | 0.98 | — | — | |
| SCHEMBL18476749 | 0.81 | NOS3 (0.59) | NOS3NOS2NOS1GABRPGABRD | |
| Bromide SCHEMBL5756336 | 0.78 | NOS3 (0.96) | NOS3NOS2NOS1GABRPGABRD | |
| SCHEMBL29481458 | 0.77 | — | — | |
| Bromide SCHEMBL16739305 | 0.77 | CCR1 (0.41) | NOS3NOS2NOS1GABRPGABRD | |
| SCHEMBL339608 | 0.77 | — | — | |
| SCHEMBL2234190 | 0.76 | NOS3 (0.63) | NOS3NOS2NOS1GABRPGABRD | |
| Hydrochloric Acid SCHEMBL23064166 | 0.76 | NOS3 (0.63) | NOS3NOS2NOS1GABRPGABRD | |
| Bromide SCHEMBL3197680 | 0.76 | PARP1 (0.39) | NOS3NOS2NOS1LOXL2LOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747242-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | Horizon Therapeutics Ireland Dac (IE) | 2026-05-27 | — | — | EP | disclosed |
| US-20250145585-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-05-08 | — | — | US | disclosed |
| WO-2025019715-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-01-23 | — | — | WO | disclosed |
| EP-3390387-B1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | Bayer Pharma AG (DE) | 2021-11-17 | — | — | EP | disclosed |
| US-10894784-B2 | Heteroarylbenzimidazole compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-01-19 | — | — | US | disclosed |
| US-20190047980-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-02-14 | — | — | US | disclosed |
| EP-3390387-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | Bayer Pharma Aktiengesellschaft (DE) | 2018-10-24 | — | — | EP | disclosed |
| US-10000471-B2 | Pyrazole P38 map kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-20170362208-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| WO-2017207534-A1 | SUBSTITUTED HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-12-07 | — | — | WO | disclosed |
| US-20130029990-A1 | PYRAZOLE P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20120171125-A1 | Methods for Enhancing the Cognitive Function | UCB PHARMA, S.A. (BE) | 2012-07-05 | — | — | US | disclosed |
| EP-2461808-A2 | METHODS FOR ENHANCING THE COGNITIVE FUNCTION | UCB Pharma S.A. (BE) | 2012-06-13 | — | — | EP | disclosed |
| WO-2011154738-A1 | UREA DERIVATIVES AND THEIR THERAPEUTIC USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-12-15 | — | — | WO | disclosed |
| WO-2011121366-A1 | PYRAZOLE P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2011-10-06 | — | — | WO | disclosed |
| EP-1717229-B1 | NOVEL CYCLIC COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP HAVING (UN)SUBSTITUTED AMINO INTRODUCED THEREIN | SANTEN PHARMACEUTICAL CO LTD (JP) | 2011-06-15 | — | — | EP | disclosed |
| WO-2011015349-A2 | METHODS FOR ENHANCING THE COGNITIVE FUNCTION | UCB PHARMA, S.A. (BE) | 2011-02-10 | — | — | WO | disclosed |
| US-7544703-B2 | Cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20070149574-A1 | Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| EP-1717229-A1 | NOVEL CYCLIC COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP HAVING (UN)SUBSTITUTED AMINO INTRODUCED THEREIN | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362208-A1 | NOVEL COMPOUNDS | ARG1, IL1B, LTB4R | NOS3 295/4885NOS2 170/4885NOS1 206/4885 |
| US-10000471-B2 | Pyrazole P38 map kinase inhibitors | MAPK1, MAP3K1, MAPK3 | NOS3 156/4885NOS2 176/4885NOS1 175/4885 |
| US-20190047980-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | CCNI, CCNT2, CDK2 | NOS3 1635/4885NOS2 1181/4885NOS1 2141/4885 |
| US-20250145585-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | IGF1R, TSHR, TRHR | NOS3 1415/4885NOS2 2020/4885NOS1 1270/4885 |
| US-20120171125-A1 | Methods for Enhancing the Cognitive Function | FABP7, CHAT, SLC18A3 | NOS3 810/4885NOS2 196/4885NOS1 586/4885 |
| US-20130029990-A1 | PYRAZOLE P38 MAP KINASE INHIBITORS | MAPK1, MAP3K1, MAPK3 | NOS3 151/4885NOS2 167/4885NOS1 184/4885 |
| US-20070149574-A1 | Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein | FLT4, FLT1, TIE1 | NOS3 142/4885NOS2 240/4885NOS1 200/4885 |
| US-10894784-B2 | Heteroarylbenzimidazole compounds | CCNI, CCNT2, CDK2 | NOS3 1635/4885NOS2 1181/4885NOS1 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.